HepCBC Reaches Inmates through Info-Fairs at 8 Federal Prisons in BC: November 5 - 9, 2018 – Abbotsford, Harrison Mills, Agassiz/Harrison Hot Springs, Mission, and Metchosin, BC
One of the most likely places to acquire and/or to be living with hepatitis C is prison, with 20-40X the national prevalence of HCV (https://ctac.ca/wp-content/uploads/2018/01/Access-to-Treatment-in-Federal-Institutions-Web-1.pdf ). Conversely, with its concentrated and highly-reg
Friday, Nov 9, 2018
News Recap:
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program.
High Prevalence of Cirrhosis in Adults with Chronic...
SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa
Of adults with chronic hepatitis B virus (HBV) infection seen at a safety-net hospital, nearly 30% had cirrhosis at initial presentation, with older male patients being at the highest risk, according to a retrospective study published in the Journal of Clinical and Experimental Hepatology.
Cirrhosis is a serious consequence of HBV infection that is associated with a financial burden of $13 billion in the United States. Delays in HBV and cirrhosis diagnosi
HepCBC Board Members: 2018-2019
Susan Malloch, R.N. (Mill Bay) – PRESIDENT (serving as President since Sept., 2016). Susan is a semi-retired orthopedic nurse. Her partner was our former Board Member Allen McCulloch who died recently while on treatment for hepatitis C. Susan knows both personally and professionally what it’s like for family members advocating for loved ones with end-stage liver disease, and wants to do what she can to help pr
Friday, Nov 2, 2018
News Recap:
Report on the Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna
The Pacific AIDS Network held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws. New Bylaws included: PAN no longer requires its hepatitis C organizational members to offer HIV-related services.
Aging and Viral Hepatitis ...
The Pacific AIDS Network (PAN – www.pacificaidsnetwork.org ) held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws.
New Bylaws included:
PAN no longer requires its hepatitis C organizational members to offer HIV-related services.
Starting with the 2019 AGM, people who are mono-infected with HCV will also be welcomed onto the
This comprehensive article which came out October 31, 2018, describes the challenges and impacts of hepatitis B and C on the aging population in Britain. It seems applicable to Canada as well.
While we couldn’t access the longer version of the article, takeaways from the abstract included:
Both hepatitis B and hepatitis C are spread through blood, are viruses, and can cause acute hepatitis (short-lasting but serious liver infection/inflammation). Bot
Patients with acute hepatitis E have higher rates of mortality compared with patients with acute hepatitis A, according to study results published in Clinical Infectious Diseases.
The results of this study also indicated that comorbid chronic hepatitis B is an independent risk factor for liver-related mortality in patients with acute hepatitis E.
“Policy makers of countries or regions endemic for [chronic hepatitis B] should be proactive to implement t
Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure—but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning 'glycolytic' enzymes in precancerous cirrhotic livers. This increase is associated with a sign
